Cargando…

Evaluation of safety of rituximab in patients with multiple sclerosis: A retrograde study

Background: The study aimed to judge the safety and possible side effects of rituximab (RTX) drug in patients with multiple sclerosis (MS). Methods: This retrospective observational study was performed on 91 patients with MS who had been treated with RTX between 2016 and 2019. Each patient was visit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Majdinasab, Nastaran, Sadrian, Mitra, Kashipazha, Davood, Moradi, Maryam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Tehran University of Medical Sciences 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8185590/ http://dx.doi.org/10.18502/cjn.v19i3.5422

Ejemplares similares

A descriptive study of prevalence, clinical features and other findings of neuromyelitis optica and neuromyelitis optica spectrum disorder in Khuzestan Province, Iran
por: Kashipazha, Davood, et al.
Publicado: (2015)

The effect of atomoxetine on cognitive function in patients with multiple sclerosis
por: Mohammadian Nejad, Ehsan, et al.
Publicado: (2023)

Association of interleukin 7 receptor gene polymorphism rs6897932 with multiple sclerosis patients in Khuzestan
por: Majdinasab, Nastaran, et al.
Publicado: (2014)

Increased frequency of CD4(+)CD25(high) CD127(low/)(−) regulatory T cells in patients with multiple sclerosis
por: Khosravi, Maryam, et al.
Publicado: (2019)

Solifenacin versus posterior tibial nerve stimulation for overactive bladder in patients with multiple sclerosis
por: Majdinasab, Nastaran, et al.
Publicado: (2023)

Several food items and multiple sclerosis: A case-control study in Ahvaz (Iran)
por: Bagheri, Maryam, et al.
Publicado: (2014)

A case–control study of drinking beverages and the risk of multiple sclerosis in Iran
por: Dastoorpoor, Maryam, et al.
Publicado: (2023)

The effect of evening primrose oil on fatigue and quality of life in patients with multiple sclerosis
por: Majdinasab, Nastaran, et al.
Publicado: (2018)

Uses of Complementary and Alternative Medicine in Multiple Sclerosis
por: Namjooyan, Foroogh, et al.
Publicado: (2014)

Effects of N‐acetylcysteine on oxidative stress biomarkers, depression, and anxiety symptoms in patients with multiple sclerosis
por: Khalatbari Mohseni, Golsa, et al.
Publicado: (2023)

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy
por: Salzer, Jonatan, et al.
Publicado: (2016)

Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study
por: Yamout, Bassem I., et al.
Publicado: (2018)

Safety of breast feeding during rituximab treatment in multiple sclerosis
por: Rød, Brit Ellen, et al.
Publicado: (2023)

Effectiveness and safety of Rituximab in multiple sclerosis: an observational study from Southern Switzerland
por: Scotti, Barbara, et al.
Publicado: (2018)

A Study on the Direct and Indirect Costs of Multiple Sclerosis Based on Expanded Disability Status Scale Score in Khuzestan, Iran
por: Torabipour, Amin, et al.
Publicado: (2014)

Serious safety events in rituximab‐treated multiple sclerosis and related disorders
por: Vollmer, Brandi L., et al.
Publicado: (2020)

Association of human leukocyte antigen-DRB haplotype in multiple sclerosis population of Khuzestan, Iran
por: Delfan, Nooshin, et al.
Publicado: (2018)

Multiple sclerosis, rituximab, and COVID‐19
por: Langer‐Gould, Annette, et al.
Publicado: (2021)

Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis
por: Zrzavy, Tobias, et al.
Publicado: (2021)

Hypogammaglobulinemia and Infections in Patients With Multiple Sclerosis Treated With Rituximab
por: Perriguey, Marine, et al.
Publicado: (2021)

Probiotic supplementation and systemic inflammation in relapsing-remitting multiple sclerosis: A randomized, double-blind, placebo-controlled trial
por: Rahimlou, Mehran, et al.
Publicado: (2022)

Validity and Reliability of the World Health Organization Disability Assessment Schedule 2.0 36-Item Persian Version for Persons with Multiple Sclerosis
por: Salehi, Reza, et al.
Publicado: (2020)

Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study
por: Torgauten, Hilde Marie, et al.
Publicado: (2021)

Corrigendum: Probiotic supplementation and systemic inflammation in relapsing-remitting multiple sclerosis: A randomized, double-blind, placebo-controlled trial
por: Rahimlou, Mehran, et al.
Publicado: (2022)

Prevalence of Sexual Dysfunction and Related Risk Factors in Men with Multiple Sclerosis in Iran: A Multicenter Study
por: Nabavi, Seyed Massood, et al.
Publicado: (2021)

Rituximab for the treatment of multiple sclerosis: a review
por: Chisari, Clara Grazia, et al.
Publicado: (2021)

Corrigendum to “Rituximab versus mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosis”
Publicado: (2021)

Efficacy and safety of rituximab in patients with multiple sclerosis: An observational study at a tertiary center in Makkah, Saudi Arabia
por: Almatrafi, Yassir M., et al.
Publicado: (2022)

Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
por: Rezaee, Mehdi, et al.
Publicado: (2022)

Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study
por: Doosti, Rozita, et al.
Publicado: (2021)

Association of HLA-DR2-Related Haplotype (HLA-DRB5*01-DRB1*1501-DQB1*0602) in Patients with Multiple Sclerosis in Khuzestan Province
por: DELFAN, Nooshin, et al.
Publicado: (2021)

Rituximab as Rescue Therapy for Aggressive Pediatric Multiple Sclerosis
por: Vartzelis, George, et al.
Publicado: (2019)

Rituximab in Multiple Sclerosis: Are We Ready for Regulatory Approval?
por: Brancati, Serena, et al.
Publicado: (2021)

Effect of Rituximab on the cognitive impairment in patients with secondary progressive multiple sclerosis
por: Salehizadeh, Saeideh, et al.
Publicado: (2022)

Prolonged COVID-19 in a Multiple Sclerosis Patient Treated With Rituximab
por: Kintrilis, Nikos, et al.
Publicado: (2022)

Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis
por: Komori, Mika, et al.
Publicado: (2016)

Treatment with Rituximab in the Acute Phase of Relapsing Remitting Multiple Sclerosis
por: Shima, Ayano, et al.
Publicado: (2019)

Discontinuation and dose reduction of rituximab in relapsing–remitting multiple sclerosis
por: Boremalm, Malin, et al.
Publicado: (2021)

COVID-19 outcomes in persons with multiple sclerosis treated with rituximab
por: Iyer, Rajesh B, et al.
Publicado: (2022)

Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience
por: Gascón-Giménez, Francisco, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gsk1gk871t9vk2i2duid18otls